Exton, Pa. – September 18, 2026 -- Kibow Biotech's redesigned website, KibowBiotech.com, has been named Best Science Website in the 2026 WebAward Competition, run by the Web Marketing Association across seven judging criteria including design, innovation, content and ease of use.

Hopewell, N.J. – September 18, 2026 -- ProBio, a global contract development and manufacturing organization (CDMO), has struck a strategic collaboration with Kun Tuo, an IQVIA-owned clinical research organization (CRO) in China, to integrate manufacturing and clinical trial execution for advanced therapies.

San Jose, Calif. – September 18, 2026 -- Anixa Biosciences (NASDAQ: ANIX) has appointed Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board as the company prepares to advance its breast cancer vaccine into a Phase 2 clinical trial and continues its ovarian cancer CAR-T therapy Phase 1 trial.

Atlanta – – September 18, 2026 -- Alzamend Neuro, Inc. (Nasdaq: ALZN) has regained compliance with Nasdaq's minimum stockholders' equity rule, ending a listing threat that began in March 2026.

Tel Aviv, Israel – September 18, 2026 -- Lutris Pharma will present updated phase 2 clinical data for its topical B-Raf inhibitor LUT014 at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, running September 30 through October 3.

Cambridge – September 18, 2026 -- Nona Biosciences has developed HCAbLM, the first language model trained specifically on fully human heavy-chain-only antibodies (HCAbs), built from a dataset of 31.8 million HCAb sequences drawn from 73 independently immunized transgenic mice. The findings were detailed in a study titled "A foundation model learns the sequence and functional grammar of fully human heavy-chain-only antibodies," published on bioRxiv.

Valby, Denmark – – September 18, 2026 -- H. Lundbeck A/S has secured marketing authorization from Japan's Ministry of Health, Labour and Welfare for eptinezumab, branded Vyepti, as a preventive treatment for migraine attacks in adults, opening the company's first independent product launch in the country.

Washington, D.C. – – September 18, 2026 -- Advocates for limb-girdle muscular dystrophy (LGMD) held more than 60 meetings with congressional offices this week, representing patients from over 20 states, as part of The Speak Foundation's LGMD Day on the Hill.

Pittsburgh – September 18, 2026 -- PhaseWell Research has acquired Community Clinical Research (CCR), an Austin, Texas-based inpatient-capable CNS clinical trial site, in a deal advised exclusively by The Braff Group. The transaction gives PhaseWell, a Shore Capital Partners portfolio company headquartered in Nashville, its first inpatient neuropsychiatric research capability.

Edina, Minn. – September 18, 2026 -- ReEmerge, Inc. has closed an oversubscribed $37 million Series A financing and exited stealth mode to advance a novel therapy targeting chronic cognitive impairment caused by traumatic brain injury (TBI).